-
2
-
-
46049090018
-
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
-
DOI 10.1378/chest.08-0685
-
Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133:776S-814S (Pubitemid 351894917)
-
(2008)
Chest
, vol.133
, Issue.6 SUPPL. 6
-
-
Becker, R.C.1
Meade, T.W.2
Berger, P.B.3
Ezekowitz, M.4
O'Connor, C.M.5
Vorchheimer, D.A.6
Guyatt, G.H.7
Mark, D.B.8
Harrington, R.A.9
-
3
-
-
0010838455
-
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
-
Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81 (Pubitemid 30240501)
-
(2000)
Lancet
, vol.355
, Issue.9215
, pp. 1575-1581
-
-
Flather, M.D.1
Yusuf, S.2
Kober, L.3
Pfeffer, M.4
Hall, A.5
Murray, G.6
Torp-Pedersen, C.7
Ball, S.8
Pogue, J.9
Moye, L.10
Braunwald, E.11
-
4
-
-
33645740812
-
Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: An overview of long-term randomized controlled trials
-
Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006;166:787-96
-
(2006)
Arch Intern Med
, vol.166
, pp. 787-96
-
-
Danchin, N.1
Cucherat, M.2
Thuillez, C.3
-
5
-
-
79952773487
-
Imagine how many lives you save: Angiotensin converting enzyme inhibition for vascular atherosclerosis in the present era of risk reduction
-
Ennezat PV, Vannesson C, Bouabdallaoui N, et al. Imagine how many lives you save: angiotensin converting enzyme inhibition for vascular atherosclerosis in the present era of risk reduction. Expert Opin Pharmacother 2011;12(6):883-9
-
(2011)
Expert Opin Pharmacother
, vol.12
, Issue.6
, pp. 883-9
-
-
Ennezat, P.V.1
Vannesson, C.2
Bouabdallaoui, N.3
-
6
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
-
DOI 10.1056/NEJM200001203420301
-
Yusuf S, Sleight P, Pogue J, et al.; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53 (Pubitemid 30051645)
-
(2000)
New England Journal of Medicine
, vol.342
, Issue.3
, pp. 145-153
-
-
Yusuf, S.1
-
7
-
-
0033860871
-
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease
-
DOI 10.1016/S0735-1097(00)00736-1, PII S0735109700007361
-
MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000;36:438-43 (Pubitemid 30624005)
-
(2000)
Journal of the American College of Cardiology
, vol.36
, Issue.2
, pp. 438-443
-
-
MacMahon, S.1
Sharpe, N.2
Gamble, G.3
Clague, A.4
Ni Mhurchu, C.5
Clark, T.6
Hart, H.7
Scott, J.8
White, H.9
-
8
-
-
0035968623
-
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
-
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
-
(2001)
Lancet
, vol.358
, pp. 1033-41
-
-
-
9
-
-
0026786643
-
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
-
The SAVE Investigators
-
Pfeffer MA, Braunwald E, Moye LA, et al.; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77
-
(1992)
N Engl J Med
, vol.327
, pp. 669-77
-
-
Pfeffer, M.A.1
Braunwald, E.2
Moye, L.A.3
-
10
-
-
0025913812
-
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
-
The SOLVD Investigators
-
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
-
(1991)
N Engl J Med
, vol.325
, pp. 293-302
-
-
-
11
-
-
0026785561
-
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
-
The SOLVD Investigattors
-
The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
-
(1992)
N Engl J Med
, vol.327
, pp. 685-91
-
-
-
12
-
-
0042330455
-
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
-
DOI 10.1016/S0140-6736(03)14286-9
-
Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8 (Pubitemid 37093919)
-
(2003)
Lancet
, vol.362
, Issue.9386
, pp. 782-788
-
-
Fox, K.M.1
-
13
-
-
19644400972
-
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
-
Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68
-
(2004)
N Engl J Med
, vol.351
, pp. 2058-68
-
-
Braunwald, E.1
Domanski, M.J.2
Fowler, S.E.3
-
14
-
-
66949162912
-
Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials
-
Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. Br J Haematol 2009;146:27-30
-
(2009)
Br J Haematol
, vol.146
, pp. 27-30
-
-
Hutton, J.L.1
-
16
-
-
0033825852
-
Choice of effect measure for epidemiological data
-
Walter SD. Choice of effect measure for epidemiological data. J Clin Epidemiol 2000;53:931-9
-
(2000)
J Clin Epidemiol
, vol.53
, pp. 931-9
-
-
Walter, S.D.1
-
17
-
-
77950189829
-
CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials
-
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332
-
(2010)
BMJ
, vol.340
-
-
Schulz, K.F.1
Altman, D.G.2
Moher, D.3
-
18
-
-
0242318334
-
Biomarkers of vascular disease linking inflammation to endothelial activation part II
-
DOI 10.1161/01.CIR.0000089093.75585.98
-
Szmitko PE, Wang CH, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: part II. Circulation 2003;108:2041-8 (Pubitemid 37337575)
-
(2003)
Circulation
, vol.108
, Issue.17
, pp. 2041-2048
-
-
Szmitko, P.E.1
Wang, C.-H.2
Weisel, R.D.3
Jeffries, G.A.4
Anderson, T.J.5
Verma, S.6
-
19
-
-
9444280103
-
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing ENdothelial Dysfunction) study
-
Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (trial on reversing endothelial dysfunction) Study. Circulation 1996;94:258-65 (Pubitemid 26266107)
-
(1996)
Circulation
, vol.94
, Issue.3
, pp. 258-265
-
-
Mancini, G.B.J.1
Henry, G.C.2
Macaya, C.3
O'Neill, B.J.4
Pucillo, A.L.5
Carere, R.G.6
Wargovich, T.J.7
Mudra, H.8
Luscher, T.F.9
Klibaner, M.I.10
Haber, H.E.11
Uprichard, A.C.G.12
Pepine, C.J.13
Pitt, B.14
-
20
-
-
0035328174
-
The Quinapril Ischemic Event Trial (QUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function
-
DOI 10.1016/S0002-9149(01)01461-8, PII S0002914901014618
-
Pitt B, O'Neill B, Feldman R, et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63 (Pubitemid 32710319)
-
(2001)
American Journal of Cardiology
, vol.87
, Issue.9
, pp. 1058-1063
-
-
Pitt, B.1
O'Neill, B.2
Feldman, R.3
Ferrari, R.4
Schwartz, L.5
Mudra, H.6
Bass, T.7
Pepine, C.8
Texter, M.9
Haber, H.10
Uprichard, A.11
Cashin-Hemphill, L.12
Lees, R.S.13
|